Ro5
The AI engine Fit Assessment
BetaRo5 leverages machine learning to enhance drug discovery, identify patterns, and expand therapeutic options, including drug repurposing efforts for COVID-19.
Blurb
Biotechnology
HQ Location
London (United Kingdom)
Founded
2018
Employees
11 - 50
Total funding raised
Not available
Last Funding Event
Acquired by Juvenescence, June 2025
Smart insights
- Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
- Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
- 6m headcount growth: 25%
- 1Y headcount growth: 94%
- Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
- Drug Repurposing
In the race to end disease and suffering, Ro5 uses artificial intelligence to cut the time and cost of drug discovery and development pipelines . . . and analytical solutions for clinical trials. For more information: www.ro5.ai